Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Binimetinib and Pembrolizumab in Advanced NSCLC
NCT03991819Phase 1Active, not recruiting
- Sponsor
- University Health Network
- Start
- Sep 2019
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of binimetinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University Health Network. Primary endpoint: Objective Response Rate at 2 years. Started Sep 2019; status: active, not recruiting.
02
Drugs
binimetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03991819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991819.